The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

• Marion Subklewe,
• Veit Bücklein,
• Cecilia Carpio,
• Frederick L Locke,
• Andreas Mackensen,
• Dimitrios Mougiakakos,
• Michael von Bergwelt-Baildon,
• Pere Barba,
• Wolfgang Bethge,
• Kai Rejeski,
• Ariel Perez,
• Gloria Iacoboni,
• Olaf Penack,
• Liv Jentzsch,
• Grace Johnson,
• Brian Arciola,
• Viktoria Blumenberg,
• Eva Hoster,
• Lars Bullinger,
• Michael D Jain

Affiliations

Marion Subklewe

Aff1 grid.411095.80000000404772585Department of Internal Medicine IIIKlinikum der Universität München, and Clinical Cooperation Group Immunotherapy at the Helmholtz Institute Munich Germany

Veit Bücklein

Aff2 grid.411095.80000000404772585Department of Internal Medicine IIIKlinikum der Universität München Germany

Cecilia Carpio

Aff41 grid.7080.fHospital Universitari Vall d’HebronUniversitat Autònoma de Barcelona Barcelona Catalonia Spain

Frederick L Locke

Department of Blood & Marrow Transplant and Cellular Immunotherapy, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

Andreas Mackensen

1 Department of Internal Medicine 5 - Hematology and Clinical Oncology, Friedrich Alexander University (FAU), Erlangen, Germany

Dimitrios Mougiakakos

1 Department of Internal Medicine 5 - Hematology and Clinical Oncology, Friedrich Alexander University (FAU), Erlangen, Germany

Michael von Bergwelt-Baildon

Department of Medicine III, Klinikum der Ludwig-Maximilians-Universitat Munchen, Munich, Germany

Pere Barba

Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), University Hospital Vall d’Hebron, Universitat Autònoma of Barcelona (UAB), Department of Medicin, Barcelona, Spain

Wolfgang Bethge

3Medical University Hospital Tübingen, Center for Clinical Studies, Tübingen, Germany

Kai Rejeski

Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany

Ariel Perez

Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA

Gloria Iacoboni

Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), University Hospital Vall d’Hebron, Universitat Autònoma of Barcelona (UAB), Department of Medicin, Barcelona, Spain

Olaf Penack

Department of Hematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

Liv Jentzsch

Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany

Grace Johnson

USF Morsani College of Medicine, Tampa, Florida, USA

Brian Arciola

USF Morsani College of Medicine, Tampa, Florida, USA

Viktoria Blumenberg

Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany

Eva Hoster

Institute for Medical Information Processing, Biometry and Epidemiology (IBE), LMU Munich, Munich, Germany

Lars Bullinger

Department of Hematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

Michael D Jain

Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA